I. Background
Immune checkpoint inhibitor plus chemotherapy has become the standard first‑line regimen for gastric cancer, yet median progression‑free survival (PFS) remains only 6–8 months, and approximately 50% of patients with low PD‑L1 expression (CPS ≤5) derive limited benefit. VEGF‑driven abnormal tumor vasculature creates an immunosuppressive microenvironment, and anti‑angiogenic therapy is expected to synergize with immunotherapy. However, most previous first‑line studies of anti‑angiogenic agents combined with chemotherapy have not demonstrated significant survival benefit across the overall population.
Against this backdrop, the team led by Prof. Ming Liu at West China Hospital of Sichuan University initiated the SBAGA study to evaluate the potential of sintilimab (a PD‑1 inhibitor), the bevacizumab biosimilar IBI305, and CapeOX chemotherapy as first‑line therapy for advanced HER2‑negative gastric/gastroesophageal junction adenocarcinoma (GA/GEJA).
II. Study Design
1. Study Type: Single‑arm, open‑label, phase Ib/II clinical trial.
Phase Ib (dose escalation): A standard “3+3” design was used to evaluate the safety of three IBI305 dose levels (7.5, 10, 15 mg/kg) and determine the recommended phase 2 dose (RP2D). The primary endpoint was dose‑limiting toxicity (DLT).
Phase II (dose expansion): Further evaluated efficacy and safety at the RP2D. The primary endpoint was objective response rate (ORR) per RECIST v1.1. Secondary endpoints included PFS, overall survival (OS), disease control rate (DCR), duration of response (DoR), and safety.
2. Treatment Regimen: Each cycle was 21 days. All patients received sintilimab (200 mg, day 1) + IBI305 (RP2D, day 1) + CapeOX (oxaliplatin 130 mg/m², day 1; capecitabine 1000 mg/m² twice daily, days 1–14) for 4–6 induction cycles, followed by maintenance therapy with capecitabine + sintilimab + IBI305 until disease progression or unacceptable toxicity.
3. Sample Size: The phase II portion planned to enroll 48 patients; ultimately 57 patients were enrolled. One phase II patient was excluded due to pathological disqualification, and two withdrew consent after completing one cycle, leaving 56 patients in the safety analysis set and 54 in the efficacy analysis set.
III. Results
1. Baseline Characteristics (FAS, N=56)
Median age was 59 years, 68% were male, and 70% had an ECOG PS of 0. Metastatic disease was present in 86%, peritoneal metastasis in 48%, CPS<1 in 25%, CPS≥1 in 66% (of whom 38% were CPS≥5, i.e., high expression), and 9% had unknown PD‑L1 status. Additionally, 93% were pMMR/MSS, 91% were EBV‑negative, and 34% had moderate/high Claudin‑18.2 expression.
2. Efficacy Data (Efficacy‑Evaluable Set, N=54)
|
Efficacy Endpoints |
Results |
|
Objective Response Rate (ORR) |
87.0% (95% CI: 75.1–94.6%) |
|
Disease Control Rate (DCR) |
98.1% (95% CI: 90.1–100.0%) |
|
Median PFS |
12.2 months (95% CI: 9.2–18.1) |
|
6-month PFS rate |
77.80% |
|
12-month PFS rate |
51.90% |
|
Median OS |
Not reached |
|
6-month OS rate |
94.40% |
|
12-month OS rate |
75.90% |
|
Median DOR |
12.5 months (95% CI: 9.4–NE) |
In key exploratory subgroup analyses, consistent clinical benefit was observed regardless of PD‑L1 CPS (<1 vs. ≥1; <5 vs. ≥5), Claudin‑18.2 expression level (negative/low vs. moderate/high), or TMB status (all P values not statistically significant). In patients with peritoneal metastasis, median PFS was 10.4 months, compared with 16.6 months in those without peritoneal metastasis (P=0.057), suggesting that this regimen may help overcome the poor prognosis associated with peritoneal involvement.
3. Safety Data (FAS, N=56)
Treatment‑related adverse events (TRAEs) occurred in 96% of patients, with grade ≥3 TRAEs in 66%, comparable to previous phase 3 studies such as CheckMate 649. The most common grade ≥3 TRAEs were neutropenia (14%), fatigue (13%), and thrombocytopenia (11%). Serious adverse events (SAEs) occurred in 20% (11/56), including gastrointestinal bleeding in 6 patients (11%) and gastric perforation in 1 patient (2%). No bleeding events were fatal; all were managed with interventions such as embolization, transfusion, and IBI305 discontinuation. Immune‑related adverse events occurred in 23% (13/56), with hypothyroidism (9 cases) being the most common. Dose reduction of any agent due to adverse events occurred in 36%; permanent discontinuation of sintilimab, IBI305, or oxaliplatin each occurred in 7% of patients.
IV. Study Highlights
Efficacy breakthrough: The triplet regimen achieved an ORR of 87.0% and a median PFS of 12.2 months, setting a new high among published data for first‑line HER2‑negative advanced gastric cancer, surpassing historical data for chemotherapy alone or PD‑1 plus chemotherapy (ORR ~45‑60%, PFS ~6‑8 months).
Coverage of “cold tumor” populations: Clear efficacy was observed in traditionally “immune‑cold” or poorer‑prognosis subgroups, including PD‑L1 low expression (CPS<1) and Claudin‑18.2 high expression, suggesting that anti‑angiogenic therapy combined with immunotherapy may expand the population benefiting from immunotherapy.
Overcoming the peritoneal metastasis challenge: In patients with peritoneal metastasis, who comprised nearly half (48%) of this cohort, the regimen also demonstrated meaningful PFS benefit (10.4 months), offering a new strategy for this difficult‑to‑treat subgroup.
Mechanistic innovation: The research team noted that, compared with multi‑target TKIs, a selective VEGF monoclonal antibody (IBI305) may avoid potential interference with lymphangiogenesis and immune cell migration, enabling better synergistic effects and more sustained treatment exposure when combined with chemotherapy and immunotherapy.
V. Conclusion
The SBAGA study demonstrated that sintilimab plus the bevacizumab biosimilar IBI305 and CapeOX chemotherapy as first‑line therapy in HER2‑negative advanced GA/GEJA patients exhibits high antitumor activity, a manageable safety profile, and clinical benefit across key biomarker subgroups. This triplet regimen provides strong evidence for overcoming current immunotherapy resistance and improving long‑term survival in advanced gastric cancer, supporting further validation in a large‑scale randomized controlled phase 3 trial. Although this is a single‑arm early‑stage study, its promising data offer hope for reshaping the future first‑line treatment landscape.
References:
[1] Cheng M, Zhang P, Hu Q, et al. Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy as a first‑line treatment in advanced gastric or gastroesophageal junction adenocarcinoma (SBAGA): a single‑arm, phase Ib/II study. Nat Commun. 2026.